Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRX NASDAQ:CING NASDAQ:LGVN NASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$4.52-3.8%$4.29$2.30▼$35.60$20.03M1.25234,986 shs22,027 shsCINGCingulate$4.52-4.4%$4.15$1.80▼$20.83$20.08M-0.791.10 million shs81,969 shsLGVNLongeveron$1.47+3.5%$1.33$1.14▼$4.88$21.20M0.21747,855 shs267,102 shsMYNZMainz Biomed$1.98+7.0%$1.90$1.34▼$19.00$6.36M0.21146,151 shs1.16 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx-3.83%+4.63%-3.62%+64.36%-85.13%CINGCingulate-4.44%+0.22%+7.62%+8.13%+1,032.83%LGVNLongeveron+3.52%-11.45%+13.08%+4.26%-62.78%MYNZMainz Biomed+7.03%+36.55%+8.20%-38.13%-88.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLRXBioLineRx2.6268 of 5 stars3.84.00.00.02.20.00.6CINGCingulate3.0731 of 5 stars3.55.00.00.02.60.80.6LGVNLongeveron3.1661 of 5 stars3.64.00.00.02.71.70.6MYNZMainz Biomed2.3596 of 5 stars3.33.00.00.00.70.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 3.50Strong Buy$26.00475.22% UpsideCINGCingulate 3.00Buy$26.00475.22% UpsideLGVNLongeveron 3.25Buy$8.67489.57% UpsideMYNZMainz Biomed 2.50Moderate Buy$14.00607.07% UpsideCurrent Analyst Ratings BreakdownLatest MYNZ, LGVN, CING, and BLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/28/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.004/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$28.94M0.67N/AN/A$4.04 per share1.12CINGCingulateN/AN/AN/AN/A$2.32 per shareN/ALGVNLongeveron$2.39M9.18N/AN/A$1.47 per share1.00MYNZMainz Biomed$890K7.65N/AN/A$2.61 per share0.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-15.21%-23.93%-6.80%8/21/2025 (Estimated)CINGCingulate-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)LGVNLongeveron-$15.97M-$6.28N/AN/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ALatest MYNZ, LGVN, CING, and BLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/ALGVNLongeveron-$0.35N/AN/AN/A$0.41 millionN/A8/12/2025Q2 2025CINGCingulate-$0.82N/AN/AN/AN/AN/A5/27/2025Q1 2025BLRXBioLineRx-$0.84$1.39+$2.23$1.39$7.72 million$11.75 million5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx0.372.272.04CINGCingulate0.161.871.87LGVNLongeveronN/A5.615.61MYNZMainz Biomed0.141.321.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%CINGCingulate41.31%LGVNLongeveron10.01%MYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%CINGCingulate17.06%LGVNLongeveron11.20%MYNZMainz BiomedN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx404.26 million4.22 millionOptionableCINGCingulate204.25 million3.52 millionNot OptionableLGVNLongeveron2014.93 million13.26 millionNot OptionableMYNZMainz Biomed303.44 millionN/ANot OptionableMYNZ, LGVN, CING, and BLRX HeadlinesRecent News About These CompaniesMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening AcquisitionJuly 15 at 8:43 AM | globenewswire.comMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening AcquisitionJuly 15 at 8:43 AM | globenewswire.comMainz Biomed BV News (MYNZ) - Investing.comJuly 4, 2025 | investing.comMainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von BauchspeicheldrüsenkrebsJune 25, 2025 | anlegerplus.deAMainz BioMed NV: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening TestJune 25, 2025 | finanznachrichten.deMainz Biomed BV Aktie | MYNZ Kurs | Realtime - Investing.comJune 25, 2025 | de.investing.comEQS-News: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von BauchspeicheldrüsenkrebsJune 25, 2025 | boerse.deBMainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening TestJune 25, 2025 | globenewswire.comPromising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy RatingJune 11, 2025 | tipranks.comMainz BioMed NV: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finanznachrichten.deMainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von BauchspeicheldrüsenkrebsJune 10, 2025 | anlegerplus.deAMainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finance.yahoo.comMainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert ProjectJune 10, 2025 | quiverquant.comQMainz Biomed N.V. Shareholders Approve Key Proposals at Annual MeetingJune 5, 2025 | tipranks.comMainz Biomed N.V. Secures $4 Million Through Securities OfferingMay 21, 2025 | tipranks.comMainz Biomed prices $4M securities offeringMay 20, 2025 | seekingalpha.comMainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and WarrantsMay 19, 2025 | investing.comMainz Biomed Announces Pricing of $4 Million Follow-On Offering and Warrant AmendmentsMay 19, 2025 | quiverquant.comQMainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and WarrantsMay 19, 2025 | globenewswire.comMainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekanntMay 16, 2025 | anlegerplus.deANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffUPS Is Outpacing the Market: A Green Light for Investors?By Jeffrey Neal Johnson | June 27, 2025View UPS Is Outpacing the Market: A Green Light for Investors?Datadog Joins S&P 500, Triggering a New Wave of UpsideBy Gabriel Osorio-Mazilli | July 7, 2025View Datadog Joins S&P 500, Triggering a New Wave of UpsideMYNZ, LGVN, CING, and BLRX Company DescriptionsBioLineRx NASDAQ:BLRX$4.52 -0.18 (-3.83%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$4.62 +0.11 (+2.32%) As of 07/15/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Cingulate NASDAQ:CING$4.52 -0.21 (-4.44%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$4.52 +0.00 (+0.09%) As of 07/15/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Longeveron NASDAQ:LGVN$1.47 +0.05 (+3.52%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.49 +0.02 (+1.43%) As of 07/15/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Mainz Biomed NASDAQ:MYNZ$1.98 +0.13 (+7.03%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.88 -0.10 (-5.05%) As of 07/15/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
